Clinical and pharmacological group: & nbsp
Insulins
Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:A.10.A.D.04 Insulin LizPro
Pharmacodynamics:Insulin lyspro soluble, in the molecule of which there is an inverse sequence of lysine and proline amino acid residues at positions 29 and 28 of the B chain of insulin, provides action for 15 minutes after administration and lasts for 2-5 hours.
It interacts with insulin receptors of fat and muscle tissues, increasing intracellular transport of glucose, simultaneously inhibits the formation of glucose in the liver. Due to the assimilation of glucose by cells, a reduction in its level in the blood plasma is achieved.
Pharmacokinetics:After subcutaneous administration quickly absorbed from the subcutaneous tissue. The maximum concentration in the blood plasma is reached in 30-70 minutes. It is distributed unevenly in the tissues. It does not penetrate the placental barrier and into breast milk.
The elimination half-life is 80 minutes.
Indications:It is used for the treatment of diabetes mellitus I type, as well as II insulin-dependent type - in combination with oral hypoglycemic agents.
IV.E10-E14.E11 Non-insulin-dependent diabetes mellitus
IV.E10-E14.E10 Insulin-dependent diabetes mellitus
Contraindications:Hypoglycemia, individual intolerance.
Carefully:Hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category B. It is used during pregnancy and lactation.
Dosing and Administration:Subcutaneously, 15 minutes before eating.
The dose is calculated individually and depends on the concentration of glucose in the blood plasma.
With diabetes mellitus II type recommended initial dose is 6 units before breakfast and 6 units before dinner in conjunction with metformin. Depending on the level of glucose in the blood plasma, the dose can be increased to 30 units per day for 2 or 3 injections.
Side effects:Central and peripheral nervous system: rapid stabilization of blood glucose levels at the beginning of therapy can lead to acute pain neuropathy, which is transient.
Dermatological reactions: lipodystrophy at the injection site.
Sense organs: refractive disorders, decreased visual acuity - is also associated with the rapid stabilization of blood glucose at the beginning of therapy, is transient.
Allergic reactions.
Overdose:Very rarely - hypoglycemia. It develops in those cases when the administered dose of the drug exceeds its need.
Treatment in mild form - ingestion of glucose (sugar, candy, sweet fruit juice).
In severe hypoglycemia - intramuscular injection of glucagon in an amount of 0.5-1 mg. Intravenous - a solution of dextrose 40% in an amount corresponding to the injected insulin preparation.
Interaction:Hypoglycemic action increases α- and β-adrenoblockers, salicylates, disopyramide, tetracyclines, monoamine oxidase inhibitors, ACE inhibitors, alcohol, sulfonamides, anabolic steroids.
Weaken the action of insulin β-adrenomimetics, glucocorticoids, sympathomimetics, thiazide diuretics.
Special instructions:Intravenous administration of the drug is carried out only in specialized departments of endocrinology.
When using insulin aspartame in insulin pumps (pumps) for subcutaneous administration, mixing of the drug with other solutions is prohibited.
Intensive physical activity, as well as concomitant infectious and inflammatory processes require an additional amount of insulin.
At the beginning It is not recommended to drive vehicles and work with moving mechanisms due to visual impairment. With constant intake of the drug should be careful in connection with the possible development of hypoglycemia.